Sentinel lymph node biopsy in breast cancer

Table of Contents

• Key Points
• Introduction: Why This Research Matters
• How This Review Was Conducted
• The History of Sentinel Lymph Node Biopsy
• How Doctors Find the Sentinel Lymph Node: Marking Techniques
• Where the Tracer Is Injected: Subareolar vs. Peritumoral
• The Question of Breast Massage
• Pathological Evaluation: Frozen Sections and Immunohistochemistry
• Who Should (and Shouldn't) Have SLNB?
• When Is Full Lymph Node Removal Still Needed?
• SLNB and Chemotherapy Before Surgery
• What This Means for Patients
• Limitations of the Research
• Recommendations for Patients
• Frequently Asked Questions
• Source Information

Key Points

• SLNB allows about 70% of patients to avoid full axillary lymph node dissection, reducing complications like lymphedema.
• Axillary recurrence after SLNB is below 2% at 8–10 years, similar to full lymph node removal.
• If fewer than 2 sentinel nodes contain metastases, skipping full node removal is safe and avoids significant morbidity.
• Newer tracers like ICG, SPIO, and microbubbles avoid radiation, but each has limitations such as skin discoloration or technical requirements.
• Most modern teams do not use routine frozen section analysis; they rely on preoperative imaging and biopsy to guide axillary staging.

Introduction: Why This Research Matters

The sentinel lymph node (SLN) is the first lymph node that receives lymphatic drainage from a tumor. Think of it as the "guard post" for the area around the cancer. If this node is free of cancer cells, the other lymph nodes in the armpit (axilla) are almost always free of cancer too — making removal of all those nodes unnecessary. Conversely, if the sentinel node does contain cancer, other nodes may also be affected, and a full axillary lymph node dissection (ALND) might be recommended in certain cases.

Sentinel lymph node biopsy (SLNB) has been studied in numerous international trials. The data consistently show that SLNB allows doctors to avoid about 70% of ALND procedures, dramatically reducing the complications associated with removing all the armpit lymph nodes. Those complications include lymphedema (persistent arm swelling), shoulder mobility problems, reduced skin sensitivity, and chronic pain.

The technique also has a second major benefit: because the sentinel node can be examined more thoroughly than the many nodes removed during a full dissection, SLNB actually leads to more accurate cancer staging. That means a more precise understanding of the disease and better-tailored treatment decisions.

Today, after a learning curve that every surgical team must complete, SLNB is routinely performed by most breast surgeons worldwide. However, many questions remain unresolved, and the technique continues to evolve. This review, written by Carole Mathelin (MD, PhD, Past President of the International Society of Senology) and Massimo Lodi, both from the Institut de cancérologie Strasbourg Europe in France, examines those questions in detail.

How This Review Was Conducted

The authors followed the PRISMA statement recommendations (a widely accepted set of guidelines for reporting research reviews). Both authors independently searched the MEDLINE database for human studies published in French or English between January 1, 1994, and August 15, 2020. They looked specifically for studies that assessed the accuracy and usefulness of SLNB in staging the armpit in breast cancer patients.

To be included, studies had to meet these criteria: (I) they involved SLNB for detecting armpit lymph node involvement in breast cancer patients; and (II) they used histopathological analysis (microscopic examination of tissue) of lymph nodes obtained by either SLNB or ALND as the reference standard.

Studies were excluded if: (I) they involved patients with metastatic armpit lymph nodes on the same side as the breast cancer; (II) no histopathological reference standard was required; (III) patients did not have breast cancer; (IV) the experiment was performed on removed tissue rather than living patients; (V) the study was a case report or letter to the editor; or (VI) the full text could not be obtained.

One author extracted the data and a second author checked it. Any disagreements were resolved through discussion. Study quality was assessed using the QUADAS (QUality Assessment of Diagnostic Accuracy Studies) checklist, a standardized tool for evaluating the quality of diagnostic studies.

The History of Sentinel Lymph Node Biopsy

Lymph node metastasis (cancer spread to lymph nodes) is one of the most important factors determining survival in many cancers. Checking the lymph nodes is essential for staging the disease, estimating prognosis, and deciding on appropriate adjuvant treatments (therapies given after the main treatment to reduce the risk of cancer returning).

The concept of the sentinel lymph node was first introduced by Cabanas in 1977 for penile cancers. However, it took almost 15 years for the technique to enter clinical practice for other cancers — with Morton and colleagues using it for melanoma in 1992 and Giuliano and colleagues adapting it for breast cancer in 1994.

The technique then spread rapidly across many types of cancer because of several medical benefits:

• It preserves normal lymph nodes, which act as an anti-tumor immunological barrier (a natural defense system against cancer)
• It allows more accurate staging by detecting hidden (occult) metastases in the sentinel node, leading to better choices of adjuvant therapy
• It is generally performed as outpatient surgery, reducing economic costs compared to full ALND

Since the early 2000s, SLNB has become a widely accepted method of lymph node staging for selected invasive and in-situ breast cancers — largely because it significantly reduces the complications associated with ALND, particularly lymphedema, shoulder adduction (arm-lifting) deficits, and numbness or tingling in the arm.

How Doctors Find the Sentinel Lymph Node: Marking Techniques

To locate the sentinel node during surgery, doctors must first "mark" it. Originally, two methods were used, both relying on non-specific marking of macrophages (scavenger cells) inside the lymph node. But this area has evolved considerably, and today there are several options.

Blue Dyes: The Traditional Approach

The biggest pitfall of SLNB is the failure to find the sentinel node, which can lead to incorrect staging, suboptimal treatment, or axillary recurrence (cancer returning in the armpit). To reduce the false negative rate, combining two methods — usually a radioisotope plus a dye — was initially recommended.

The first dyes used were triarylmethane dyes, including patent blue (used widely in Europe) and its isomer isosulfan blue dye, also called lymphazurin (used in the United States). These dyes bind to proteins in the blood and lymphatic fluid. Their particle size is small enough to travel through lymph vessels but large enough to get trapped in the sentinel node. Clinical studies reported high detection rates with both.

Methylene blue dye (MBD) is a smaller molecule that does not bind to plasma proteins. In a feline model, Wong et al. showed that when MBD was injected into the skin, it was less effective at defining lymphatic drainage because of poor uptake into the lymphatics and tissue staining. As a result, MBD was not initially adopted for SLNB.

That changed in 2001. Simmons et al. published the first study of MBD injection for SLNB in breast cancer, describing localization rates of 90% — unexpectedly comparable to isosulfan blue and patent blue. This study opened the door for MBD as a much cheaper alternative.

The Allergy Problem with Blue Dyes

It soon became clear that isosulfan blue and patent blue were associated with a significant number of allergic reactions. The rate ranged from 0.1% to 3%, and some reactions were life-threatening.

For example, two large multicenter, randomized studies conducted in the United Kingdom — the ALMANAC and NEW START trials — found that 72 out of 7,917 patients (0.9%) had allergic reactions to patent blue.

Patent blue is also a food colorant. It has been banned in the United States and several other parts of the world due to its side effects. It is still allowed in the European Union, although when the European Food Safety Authority re-evaluated it in 2013, its acceptable daily intake was lowered.

Compounding the problem, an international shortage of isosulfan blue in the 2000s triggered a rush to find alternative dyes for SLN mapping.

Methylene Blue: A Safer, Cheaper Option

Methylene blue is widely used in many diagnostic and therapeutic procedures — for nipple discharge surgery, fallopian tube patency evaluation, chromoendoscopy, and more. It has rarely been associated with life-threatening adverse events.

However, MBD does have its own issues. Localized reactions to intradermal (into-the-skin) injections for SLNB have been described, including necrosis of skin and subcutaneous tissues (tissue death) and necrotic abscesses. For this reason, doctors now recommend injecting MBD into the breast tissue itself (intraparenchymal injection) rather than into the skin.

MBD is also contraindicated in patients with glucose-6-phosphate dehydrogenase deficiency, thalassaemia, or drepanocytosis (sickle cell disease), because it may worsen methemoglobinaemia (a blood disorder affecting oxygen delivery) or trigger haemolytic anaemia (destruction of red blood cells).

Radioisotopes: The Nuclear Medicine Approach

Combining techniques — for example, a radioisotope plus a dye — is recommended to avoid the failure to identify the sentinel node, which would otherwise force a complete ALND. Radioisotopes have an added advantage: they allow pre-operative imaging of the sentinel node by lymphoscintigraphy.

The typical procedure works like this:

1. A radioactive solution (technetium-99m colloidal, abbreviated 99mTc) is injected into the subareolar area (behind the nipple) or around the tumor (peritumoral area)
2. A few hours later, lymphoscintigraphy is performed with a gamma camera to map the drainage
3. Surgery usually happens the next day, beginning with injection of a blue dye in the same areas
4. During the operation, a handheld probe detects the radioactive nodes
5. All labeled or dyed nodes are removed individually and sent for pathological examination

How Much Radioactivity Is Safe?

One major unresolved question is the amount of radioactivity that should be injected. Despite SLNB being widely used since the 2000s, the injected dose varies enormously between medical teams — ranging from 1.8 to 370 MBq (megabecquerels, the unit of radioactivity).

The Society of Nuclear Medicine and Molecular Imaging and the European Association of Nuclear Medicine recommend administering 50 MBq when the injection happens the day before surgery. Only van der Ent et al. claimed that higher doses improved detection sensitivity, and no other studies confirmed this.

Radiation Exposure for Staff: The Numbers

Bailly et al. studied radiation exposure for nursing and medical staff during breast surgery. Their prospective study measured radiation doses to staff directly. The mean activity of injected 99mTc-colloids was 50.1±2.4 MBq (when injected the day of surgery) and 90.4±3.2 MBq (when injected the day before).

The average radiation doses received per procedure were:

• Surgeon: 5 µSv whole body, 17.5 µSv extremity (hands/fingers)
• Surgical assistant: 3.75 µSv whole body, 15.6 µSv extremity
• Nurse: 0 µSv whole body, 16.2 µSv extremity

The authors concluded that for surgeons performing fewer than 30 SLNB procedures per year, radiation exposure stayed below regulatory annual thresholds. But here's the concern: French and European regulations, following the International Commission on Radiological Protection, set the annual limit of whole-body effective dose for the public at 1 mSv over 12 consecutive months. That 1 mSv limit corresponds to the exposure of a surgeon performing about 200 SLNB procedures.

And that number is easily reached — breast cancer is the most common cancer in women, and SLNB is now routine for it. A surgeon specializing in senology (the study of breast disease) can easily perform 200 SLNB procedures per year.

Low-Dose Injections: A Safer Alternative?

Some teams use low-dose injections — about 16 MBq on average — the day before surgery. In a prospective clinical trial, these low doses still achieved SLN identification in 99% of cases (94% of sentinel nodes were "hot" — meaning radioactive — and 65% were stained with dye).

Dosimetric measurements using thermoluminescent dosimeters showed mean exposure levels per procedure of just 4.7±2.6 µSv at the surgeon's index finger and whole-body exposure of less than 1 µSv.

Extrapolating to 200 procedures per year, a single surgeon would receive an extremity dose of 940 µSv — more than 50 times lower than the regulatory limit for the public for extremities (50 mSv per 12 months). This confirms that it's possible to dramatically reduce medical staff exposure without losing the ability to detect sentinel nodes during surgery.

Indocyanine Green (ICG): A Fluorescent Alternative

Researchers have developed new tracers to overcome the downsides of radioisotopes (radiation exposure and the need for a nuclear medicine center) and blue dyes (allergic reactions). Three innovative options stand out: indocyanine green (ICG), superparamagnetic iron oxide (SPIO), and microbubbles.

ICG is a fluorescent dye. After injection into breast tissue, it migrates through lymphatic vessels and is tracked using an excitation illumination system with a camera that detects the emitted fluorescence in the near-infrared spectrum.

ICG has been used in medicine since the 1950s, and specifically for breast cancer since the last decade. Its advantages include:

• Real-time detection through the skin (transcutaneous detection), helping surgeons see nodes before cutting
• No radiation exposure
• Lower cost than radioisotopes
• No need for a nuclear medicine department — making it valuable in resource-limited settings

But there are drawbacks. It requires a specialized intraoperative fluorescence imaging system and the ability to operate under dimmed lighting — which can interfere with surgery. After removing the first sentinel node, ICG can leak into the surgical field, making it harder to find subsequent nodes. Its low molecular weight means it may travel faster than blue dye, potentially leading to unnecessarily extensive dissection and removal of more nodes than needed.

In fact, a recent meta-analysis found a higher mean number of sentinel nodes removed with ICG (1.31–3.8) compared to radioisotopes (1.35–2.3). Yet, detection rates for ICG — with or without blue dye — appear equivalent to the gold standard combination of blue dye plus radioisotopes, or radioisotopes alone. The meta-analysis found similar detection rates between ICG and radioisotopes used alone, with even better results when the two techniques were combined.

The overall conclusion: ICG is a good alternative to blue dye and radioisotopes, particularly suitable for surgical teams working without access to a nuclear medicine department.

Superparamagnetic Iron Oxide (SPIO): A Magnetic Approach

The SPIO method uses a magnetic tracer made of iron oxide nanoparticles coated in carbohydrates. The tracer is injected and migrates through lymph vessels into the sentinel node. A handheld magnetometer then generates an alternating magnetic field that temporarily magnetizes the SPIO particles and senses their magnetic response.

Developed in 2013 by an international European team, SPIO has some distinctive advantages:

• The magnetic tracer fades slowly and remains detectable for several months after injection
• It can be injected anywhere from 15 days before surgery to immediately before the skin incision — a very comfortable timeframe
• The brown color of the tracer can help guide dissection during surgery
• No radiation exposure, and no nuclear medicine department required

However, SPIO also has significant limitations:

• Dermopigmentation (permanent skin discoloration) occurs in up to 20% of patients
• The intramammary persistence of the tracer can create void artifacts (blank spots) that complicate the interpretation of post-operative breast MRI scans
• Patients with pacemakers are not eligible, because the magnetic field can cause heart rhythm disorders
• Metallic surgical instruments can interfere with the ferromagnetic signal

A meta-analysis of 7 studies published in 2016 found that SPIO was not inferior to the standard technique regarding identification rate, but it had a significantly higher lymph node retrieval rate — which could lead to unnecessarily excessive dissection.

Microbubbles: Ultrasound-Guided Detection

Another alternative is contrast-enhanced ultrasound imaging using microbubbles. These phospholipid-stabilized microbubbles contain sulphur hexafluoride gas. After intradermal injection, they migrate through lymphatics and act as sonographic contrast agents, making the sentinel node visible on ultrasound.

The technique was initially developed in 2004 to trace lymphatic drainage in a swine model with melanoma, and was first studied in breast cancer patients in 2006. Like ICG and SPIO, it requires no radioisotope and no nuclear medicine department.

Advantages include real-time visualization of the sentinel node, a cheap contrast agent, and no risk of allergy — since the microbubbles contain no iodine and no proteins.

The downsides? The technique is slower than others, requires skill in axillary ultrasound examination, has a longer learning curve, and remains operator-dependent. It also has a lower detection rate compared to blue dye, and lower sensitivity.

Where the Tracer Is Injected: Subareolar vs. Peritumoral

Another question researchers have studied is whether it matters where the tracer is injected. Studies comparing subareolar injection (behind the areola) with peritumoral injection (around the tumor) using various markers — blue dyes and isotopes — have found no difference between the two approaches.

The distribution of the number of nodes removed is also strictly the same, with a significant proportion of cases having one or two sentinel nodes in both groups. These findings support the concept of a "single biological entity" of the sentinel node for the entire mammary gland — meaning the whole breast drains to the same first node, regardless of where in the breast the tumor sits.

The Question of Breast Massage

In some centers, breast massage (5 to 10 minutes) was performed after injection of the radioisotope or dye, in hopes of improving uptake of the markers into the sentinel node. Various massage techniques were evaluated, but none proved superior to the others.

More concerning, researchers raised the worry that breast massage — through mechanical transport — might push epithelial cells (surface cells from the breast ducts) into the sentinel node, producing false-positive findings of occult metastases. Diaz et al. found that epithelial cells (without features of established metastases) appeared more frequently in the sentinel nodes of patients who underwent breast massage.

The significance of this is debated. Even though the presence of isolated tumor cells (ITCs) does not alter clinical management, it has been associated with a worse prognosis in some published series. Since there is no proof that breast massage is safe, and no demonstrated benefit with current techniques, breast massage is no longer performed in routine clinical practice.

Pathological Evaluation: Frozen Sections and Immunohistochemistry

In the past, many surgeons performed intraoperative frozen section analysis — rapidly freezing the sentinel node during surgery and examining it under a microscope — to determine immediately whether an ALND was needed, avoiding a second operation.

Today, most teams have abandoned this practice. Why? Frozen section analysis has a low impact on reoperation rates, while adding significant time and cost to surgery. Instead, doctors now rely on:

• Precise preoperative imaging of the armpit, especially ultrasound, often followed by fine-needle aspiration or core needle biopsy of any abnormal lymph nodes
• Additional imaging techniques such as MRI and FDG-PET (fluoro-deoxy-glucose positron emission tomography) scans

The development of preoperative imaging has had a major impact on how the armpit is staged, reducing the need for intraoperative decisions.

The Role of Immunohistochemistry (IHC)

To determine the pathologic nodal (pN) stage, pathologists traditionally examined multiple tissue levels and performed immunohistochemistry (IHC) — a staining technique using antibodies — to increase the detection of occult (hidden) lymph node metastases. Occult metastases are tumor cells that weren't identified during the initial assessment of a stained section.

Sentinel nodes were generally analyzed after staining with haematoxylin-eosin (H&E). Thorough examination involved sectioning the entire node into 2 mm thick blocks, with duplicate paraffin-embedded sections cut at different intervals. Nodes that looked cancer-free with H&E staining were then tested with IHC using an anti-keratin antibody, which can identify tumor cells that regular staining misses. This allowed detection of three categories:

• Isolated tumor cells (ITC) — single cells or small clusters, not forming true deposits
• Micrometastases — small deposits between 0.2 mm and 2 mm
• Macrometastases — larger deposits over 2 mm

But it quickly became clear that patients with very limited sentinel node involvement (ITCs or micrometastases) did not benefit from ALND. The numbers tell the story:

• A retrospective analysis of the NSABP B-32 trial found a 15.9% increase in the detection of occult metastases when IHC was used — and 72% of those occult metastases were ITCs
• The ACOSOG Z0010 trial found a 10.5% prevalence of occult metastases when IHC was used

Because IHC results were not changing treatment decisions, in 2010 the American Joint Committee on Cancer reclassified the staging system. Today, routine IHC for sentinel node evaluation is no longer recommended — it only adds information that usually doesn't change what doctors do, and in some cases could lead to unnecessary ALND.

Who Should (and Shouldn't) Have SLNB?

The indications for SLNB in invasive breast cancer are specific. The technique is appropriate for tumors staged T0, T1, or T2 (meaning the tumor is no larger than 5 cm) with N0 or N1 nodal status — that is, no suspicious lymph nodes, or nodes that have been accurately evaluated with ultrasound and/or cytology or core biopsy and found to be clear or minimally involved.

For ductal carcinoma in situ (DCIS — a non-invasive cancer confined to the milk ducts), SLNB is indicated in two situations:

• When the DCIS is being treated with mastectomy (because a full breast removal means the sentinel node can no longer be mapped later)
• When the DCIS presents as a palpable mass (because a mass-like DCIS has a higher risk of being invasive)

Contraindications to SLNB fall into two categories. The absolute contraindication is the presence of metastasized (cancer-containing) lymph nodes confirmed by biopsy — in that case, ALND is the standard approach. All other contraindications aim to avoid situations where the risk of a false negative result (missing cancer that's actually there) would be too high. That includes:

• T3 or T4 tumors (tumors larger than 5 cm, or tumors that have spread to the chest wall or skin)
• Multicentric tumors (cancers in more than one location in the breast)

When Is Full Lymph Node Removal Still Needed?

After SLNB, the decision about whether to proceed with a full ALND depends on what the sentinel node shows. The research provides clear guidance:

• When the sentinel node contains fewer than 2 metastases, axillary recurrence rates remain low even when ALND is omitted
• When there are more than 2 metastatic sentinel nodes, or when the cancer has broken through the lymph node capsule (capsular effraction), ALND is still indicated

This is a crucial finding for patients. It means that having cancer found in one sentinel node doesn't automatically mean you need the full lymph node dissection — in fact, for limited involvement, skipping the ALND is safe and avoids significant morbidity.

The long-term outcomes are reassuring. After SLNB, axillary recurrence rates are generally below 2% after 8–10 years of follow-up — comparable to recurrence rates observed after full ALND. This is powerful evidence that when the sentinel node is negative, leaving the remaining nodes alone is the right call.

SLNB and Chemotherapy Before Surgery

Neoadjuvant systemic therapy (NST) — chemotherapy or other systemic treatments given before surgery to shrink the tumor — raises its own set of questions about timing and accuracy of SLNB.

The evidence supports that for most teams, SLNB can be performed in clinically node-negative patients receiving neoadjuvant systemic therapy. In other words, if imaging and examination show no signs of cancer in the armpit lymph nodes before treatment starts, SLNB can safely be done after the neoadjuvant therapy is complete, at the time of the definitive breast surgery.

This timing matters because neoadjuvant therapy can sometimes sterilize (eliminate) cancer cells in lymph nodes. Knowing whether the nodes still contain cancer after treatment provides crucial information about how well the therapy worked and what further treatments might be needed.

What This Means for Patients

The evidence reviewed here carries several clear implications for patients facing breast cancer surgery:

First, ask about SLNB. For most patients with early-stage breast cancer (T0–T2, N0–N1), sentinel node biopsy is the standard of care — not full lymph node removal. It avoids about 70% of ALND procedures and dramatically reduces the risk of lymphedema, shoulder problems, numbness, and pain.

Second, know your tracer options. You may have a choice in how your sentinel node is identified. The traditional approach combines a radioisotope (with a nuclear medicine injection) and a blue dye. Newer options like ICG, SPIO, and microbubbles avoid radiation entirely. Each has pros and cons — SPIO leaves skin discoloration in up to 20% of patients and isn't safe with pacemakers; ICG requires dimmed lighting in the operating room; microbubbles require special ultrasound expertise. Ask your surgeon about what's available at your center.

Third, if allergic reactions worry you, speak up. Patent blue and isosulfan blue cause allergic reactions in 0.1–3% of patients. Methylene blue is a cheaper alternative with fewer allergy concerns, though it has other precautions (it should not be used if you have G6PD deficiency, thalassaemia, or sickle cell disease).

Fourth, know that a positive sentinel node doesn't always mean full node removal. If the sentinel node contains less than 2 metastases, skipping ALND is safe and is supported by strong evidence showing low recurrence rates. Full dissection is generally reserved for cases with more than 2 involved nodes or when cancer has spread through the node capsule.

Fifth, be reassured by the long-term safety data. Axillary recurrence after SLNB is below 2% at 8–10 years — comparable to the much more invasive ALND.

Limitations of the Research

This review, while comprehensive, has several limitations that patients should understand.

First, it is a narrative review, not a systematic meta-analysis. While the authors followed PRISMA reporting guidelines and conducted a structured literature search, the synthesis of evidence is qualitative rather than statistical. The authors didn't pool all data mathematically to reach a single combined estimate.

Second, the data on some newer tracers — ICG, SPIO, and microbubbles — come from a limited number of studies with varying quality. The meta-analyses cited are based on relatively few trials, and some comparisons (like SPIO's higher node retrieval rate) could reflect differences in surgical technique rather than true tracer superiority.

Third, the review covers studies up to August 15, 2020. Since the technique continues to evolve, newer evidence published after this date is not included. Readers should clarify with their care teams whether recent developments affect current recommendations.

Fourth, much of the evidence base comes from high-volume, specialized centers. SLNB's excellent results depend heavily on surgical experience — the learning curve is real, and results in low-volume centers may not match those in specialized institutions.

Fifth, several questions remain genuinely unresolved, as the article title emphasizes. These include the optimal radioisotope dose, the ideal injection site (though current data shows no difference), the place of ambulatory (outpatient) surgery, the precise indications for ALND after SLNB, and the role of MRI and PET in axillary staging.

Recommendations for Patients

Based on this review, here is practical advice for patients preparing for breast cancer surgery:

1. Ask whether you are a candidate for SLNB. Most patients with tumors up to 5 cm (T0–T2) and no suspicious nodes are eligible. If you have DCIS and are having a mastectomy, or your DCIS feels like a lump, SLNB is recommended.
2. Discuss your tracer options with your surgeon. Ask whether your center uses radioisotopes, blue dye, ICG, SPIO, or microbubbles — and which is recommended for your specific situation.
3. Mention any allergies or medical conditions that could affect tracer choice, including a history of allergic reactions to dyes, G6PD deficiency, thalassaemia, sickle cell disease, or the presence of a pacemaker.
4. Expect accurate pre-operative imaging. A thorough axillary ultrasound, with biopsy of any abnormal nodes, should be part of your workup before surgery.
5. Ask about your frozen section protocol. Most modern teams do not perform routine intraoperative frozen section analysis. It adds time and cost without meaningfully reducing reoperation rates.
6. If you're having chemotherapy before surgery, ask how SLNB will be timed. The evidence supports performing SLNB after neoadjuvant therapy in clinically node-negative patients.
7. Seek a high-volume, experienced team. SLNB is extremely reliable when performed rigorously by surgeons who have completed multidisciplinary training and gained sufficient experience. The learning curve matters, and results are best at specialized centers.

Finally, understand the big picture. SLNB is not just a less invasive alternative to ALND — it is a better staging tool in many ways. It allows pathologists to examine the most relevant nodes thoroughly, leading to more accurate staging and smarter treatment decisions. When performed by experienced teams on carefully selected patients, it is consistently shown to be extremely reliable. The technique is in constant evolution, but its core promise remains: accurate information about whether your cancer has spread, with far less harm to your body.

Frequently Asked Questions

What is a sentinel lymph node biopsy (SLNB) and why is it done?

SLNB is a surgical procedure that removes the first lymph node receiving drainage from a breast tumor. If that node is cancer-free, other armpit nodes are usually also cancer-free, so removing them all is unnecessary. This helps stage breast cancer accurately while avoiding more invasive lymph node removal.

Am I a candidate for sentinel lymph node biopsy?

You are typically a candidate if you have invasive breast cancer staged T0, T1, or T2, meaning the tumor is no larger than 5 cm, and your lymph nodes appear clear or minimally involved on imaging. For DCIS, SLNB is recommended if you are having a mastectomy or if the DCIS feels like a lump.

What tracers are used to find the sentinel lymph node?

The traditional approach combines a radioactive tracer (technetium-99m) with a blue dye. Alternatives include indocyanine green (ICG), a fluorescent dye; superparamagnetic iron oxide (SPIO), a magnetic tracer; and microbubbles for ultrasound guidance. Each has advantages and disadvantages, such as skin discoloration with SPIO or allergic reactions with blue dyes.

What are the risks or side effects of sentinel lymph node biopsy?

SLNB avoids about 70% of full lymph node removals, greatly lowering risks like lymphedema, shoulder problems, numbness, and pain. However, blue dyes can cause allergic reactions in 0.1–3% of patients. Methylene blue, a cheaper alternative, can cause skin necrosis if injected into the skin, so it is injected into breast tissue instead.

If my sentinel node contains cancer, do I always need full lymph node removal?

No. If fewer than 2 sentinel nodes contain metastases, skipping full lymph node removal is safe, with low axillary recurrence rates. Full dissection is generally reserved for cases with more than 2 involved nodes or when cancer has spread through the node capsule.

How reliable is sentinel lymph node biopsy in preventing cancer from returning in the armpit?

When performed by experienced teams, SLNB is extremely reliable. Axillary recurrence rates after SLNB are generally below 2% after 8–10 years of follow-up, comparable to recurrence rates after full axillary lymph node dissection. This long-term data shows that leaving negative nodes alone is safe.

Can I have SLNB if I need chemotherapy before surgery?

Yes, for most patients with no signs of cancer in armpit lymph nodes before treatment, SLNB can be safely performed after neoadjuvant chemotherapy, at the time of definitive breast surgery. This timing tells your team whether the chemotherapy eliminated cancer cells in the nodes, guiding further treatment decisions.

Should I get a second opinion before deciding whether to have sentinel lymph node biopsy or full lymph node removal for breast cancer?

Sentinel lymph node biopsy (SLNB) is standard for early-stage breast cancer and avoids about 70% of full axillary lymph node dissections, lowering risks like lymphedema. Even if a sentinel node contains cancer, full dissection is not always needed when fewer than two metastases are present; recurrence rates remain below 2% at 8–10 years. However, unresolved questions exist about tracer choice, injection site, and timing with neoadjuvant chemotherapy. A second opinion can confirm your surgical plan and explore alternatives. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original Article: "Narrative review of sentinel lymph node biopsy in breast cancer: a technique in constant evolution with still numerous unresolved questions"

Authors: Carole Mathelin, MD, PhD and Massimo Lodi — Service de chirurgie, Institut de cancérologie Strasbourg Europe (ICANS), Strasbourg, France; and Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), France.

Journal: Chinese Clinical Oncology, Vol 10, No 2, April 2021. Published online as Review Article, Page 1 of 14.

Published: Submitted August 21, 2020; Accepted November 23, 2020. DOI: 10.21037/cco-20-207

Corresponding Author: Carole Mathelin, MD, PhD, Past President of the International Society of Senology (SIS). Email: C.Mathelin@icans.eu

This patient-friendly article is based on peer-reviewed research published in Chinese Clinical Oncology. It is intended for educational purposes and does not replace individualized medical advice from your healthcare team. Always discuss your specific treatment options with your doctors.